OncoC4
- Biotech or pharma, therapeutic R&D
OncoC4 is a late clinical-stage biopharmaceutical company targeting innate and adaptive immune checkpoints to treat cancer, neurodegeneration, and other diseases. OncoC4 aims to develop best-in-class programs for validated targets such as PD-1/VEGF & CTLA-4, and first-in-class programs targeting Siglec-10 & CD24:
• AI-081, a potentially best-in-class PD-1/VEGF bsAb undergoes a Phase 1/2 study in solid tumors in US
• ONC-841, the first-in-class Siglec-10 mAb, is near end of Phase 1 in cancer
• IND-enabling studies ongoing for T-cell engager and antibody-drug conjugates (ADC) based on proprietary Neo-CD24 targeting antibody
————
AdaMunix, an OncoC4 spinoff, offers a disruptive platform to eliminate anti-drug antibodies (ADA). Leveraging unique B-cell biology, AdaMunix has advanced three programs to the pre-IND stage.
In preclinical studies, we have demonstrated near-complete ADA elimination for several approved drugs, positioning AdaMunix as a leader in targeted ADA solutions.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}